Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 28 versus ZOVIA 1 50E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 28 versus ZOVIA 1 50E 21.
LESSINA-28 vs ZOVIA 1/50E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
Combination estrogen-progestin contraceptive: Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; Norethindrone induces cervical mucus thickening and endometrial thinning, impeding sperm penetration and implantation.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life: 13±3 hours (range 10-20 h) for the progestin component; clinical context: steady-state achieved within 5 days, with minimal accumulation.
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Renal: ~50% (metabolites); Fecal: ~30% (metabolites); Biliary: minor; Unchanged drug: <1% renal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive